迈威生物携手齐鲁制药，引领生物医药行业“研发+商业化”新趋势

Core Viewpoint - The collaboration between Maiwei Biopharma and Qilu Pharmaceutical reflects a new trend in the biopharmaceutical industry, where innovative drug companies focus on R&D while traditional pharmaceutical companies handle commercialization through technology licensing [1][2] Company Summary - Maiwei Biopharma has signed a technology licensing agreement with Qilu Pharmaceutical for the injectable drug Aggrastat α (trade name: Mai Li Sheng), granting exclusive rights for development, production, improvement, utilization, and commercialization in Greater China [1] - The agreement includes an upfront payment and milestone payments totaling up to 500 million RMB, along with royalties based on net sales of the licensed product [1] Product Summary - Aggrastat α is a recombinant human serum albumin-granulocyte colony-stimulating factor (G-CSF) fusion protein, designed to reduce the incidence of infections in adult patients undergoing chemotherapy that causes febrile neutropenia [1][2] - This product is the first approved drug in China utilizing albumin fusion technology, which enhances the drug's half-life and reduces dosing frequency, thereby improving patient compliance [2] - The production process utilizes a Pichia pastoris expression system, simplifying manufacturing and improving product uniformity compared to chemically modified long-acting products [2] Industry Trend - The partnership exemplifies a model that allows innovative drugs to reach patients more quickly and cost-effectively, contributing to a biopharmaceutical ecosystem characterized by specialized R&D, large-scale production, and refined commercialization [2]